advertisement

---

Mardin CY 9

Showing records 1 to 9 | Display all abstracts from Mardin CY

82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Hohberger B
Frontiers in immunology 2019; 10: 2112

---

82394 OCT Angiography: Measurement of Retinal Macular Microvasculature with Spectralis II OCT Angiography - Reliability and Reproducibility
Hosari S
Ophthalmologica 2020; 243: 75-84

---

82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Kunze R
Frontiers in immunology 2019; 10: 2112

---

82394 OCT Angiography: Measurement of Retinal Macular Microvasculature with Spectralis II OCT Angiography - Reliability and Reproducibility
Hohberger B; Theelke L
Ophthalmologica 2020; 243: 75-84

---

82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Wallukat G; Kara K
Frontiers in immunology 2019; 10: 2112

---

82394 OCT Angiography: Measurement of Retinal Macular Microvasculature with Spectralis II OCT Angiography - Reliability and Reproducibility
Sari H; Lúcio M
Ophthalmologica 2020; 243: 75-84

---

82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Mardin CY; Lämmer R
Frontiers in immunology 2019; 10: 2112

---

82394 OCT Angiography: Measurement of Retinal Macular Microvasculature with Spectralis II OCT Angiography - Reliability and Reproducibility
Mardin CY
Ophthalmologica 2020; 243: 75-84

---

82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Schlötzer-Schrehardt U; Hosari S; Horn F; Muñoz L; Herrmann M
Frontiers in immunology 2019; 10: 2112

---